A century of research later, and we’re still not sure what causes it

"The high price of Leqembi threaten Medicare's finances, it will also negatively impact seniors on fixed incomes"

Fast-track approval of three risky drugs intends to slow the disease, but evidence they benefit patients is shaky

Studying the brains of beached dolphins revealed familiar signs of Alzheimer's disease

There's still no established cause for Alzheimer's, but emphasizing some symptoms can have unintended consequences

Americans age 60 and over identify the disease as their single greatest fear. Here's how it works and who's at risk

New Alzheimer's drug, approved by the FDA over much uproar, accounts for half of Medicare's yearly price increase

Could blood tests aid in diagnosing? A new study says yes

We talked to Patti Davis and Andrew K. Budson about their respective new books on caregiving and dementia

Outstanding doubts about Leqembi and related drugs have given urgency to efforts to monitor patient experiences

Repeat after us, you're not dying in a terrorist attack. Cancer and heart disease pose far, far greater threats

From "old-timers' disease" to "happy as a clown," these eggcorns are wrong yet seem so right

Will lumbering MAGAsaurs do battle? Stone throws down "gauntlet" to "sloppy Steve" in Infowars appearance

Leqembi has proven to slow the progression of the disease, while others only target its symptoms

Latest HHS move should alarm "every Congressional Democrat who wants to keep their seat in November"